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Background & Aims:
The efficacy and tolerability of faldaprevir, a potent hepatitis C virus (HCV) NS3/4A protease inhibitor, plus peginterferon and ribavirin was assessed in a double-blind, placebo-controlled phase 3 study of treatment-naïve patients with HCV genotype-1 infection.
Methods:
Patients were randomly assigned (1:2:2) to peginterferon/ribavirin plus: placebo (arm 1, n=132) for 24 weeks; faldaprevir (120 mg, once daily) for 12 or 24 weeks (arm 2, n=259); or faldaprevir (240 mg, once daily) for 12 weeks (arm 3, n=261). In arms 2 and 3, patients with early treatment success (HCV RNA <25 IU/mL at week 4 and undetectable at week 8) stopped all treatment at week 24.
Other patients received peginterferon/ribavirin until week 48 unless they met futility criteria. The primary endpoint was sustained virologic response 12 weeks posttreatment (SVR12).
Results: SVR12 was achieved by 52%, 79%, and 80% of patients in arms 1, 2, and 3, respectively (estimated difference for arms 2 and 3 versus arm 1: 27%, 95% confidence interval 17%-36%; and 29%, 95% confidence interval, 19%-38%, respectively; P<.0001 for both). Early treatment success was achieved by 87% (arm 2) and 89% (arm 3) of patients, of whom 86% and 89% achieved SVR12. Adverse event rates were similar among groups; few adverse events led to discontinuation of all regimen components.
Conclusions:
Faldaprevir plus peginterferon/ribavirin significantly increased SVR12, compared with peginterferon/ribavirin, in treatment-naïve patients with HCV genotype-1 infection. There do not seem to be any differences in responses of patients given once-daily 120 or 240 mg faldaprevir.
Introduction
The introduction of the hepatitis C virus (HCV) NS3/4A protease inhibitors (PI) telaprevir and boceprevir represented a major advance in the treatment of chronic HCV genotype-1. Telaprevir or boceprevir with peginterferon and ribavirin resulted in a sustained virologic response (SVR) in 63%-75% of treatment-naïve patients, compared with 38%-44% with peginterferon and ribavirin alone [1] [2] [3] [4] . However, these drugs have limitations, including serious skin reactions with telaprevir [5] , and an increased incidence of anemia, compared with peginterferon and ribavirin alone, with both telaprevir and boceprevir [1] [2] [3] [4] . Furthermore, both drugs also display a wide range of drug-drug interactions (DDIs), have a high pill burden, and require twice-daily (BID) or three-times-daily dosing [5] [6] [7] [8] [9] .
Faldaprevir (BI 201335) is a potent HCV NS3/4A PI administered once daily [10] [11] [12] .
Four phase 2 studies evaluated the efficacy and safety of faldaprevir with peginterferon alfa-2a plus ribavirin [13] [14] [15] [16] . In genotype-1 treatment-naïve patients, SVR rates of up to 84% were achieved compared with 56% for placebo plus peginterferon and ribavirin [13] . In addition, SVR rates were similar with faldaprevir 120 mg for 12 or 24 weeks [16] . The addition of faldaprevir to peginterferon and ribavirin was not associated with an increased incidence of anemia compared with peginterferon and ribavirin alone [13, 16] and there have been no reports of potentially life-threatening cutaneous adverse reactions in phase 2 studies [13, 14, 16] . Studies of faldaprevir and antiretrovirals have shown a lower potential for DDIs than first-wave PIs [17] .
STARTVerso1 was a phase 3 study designed to assess the efficacy and safety of faldaprevir with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype-1 infection.
Patients and methods

Patients
Patients were recruited from nine European countries and Japan. Eligible patients were treatment-naïve, aged 18-70 years (Europe), or 20-70 years (Japan), with chronic HCV genotype-1 infection diagnosed by positive anti-HCV antibodies and HCV RNA ≥1000 IU/mL at screening plus a positive antibody or HCV RNA test more than 6 months before screening, or a liver biopsy consistent with chronic HCV infection.
Patients with compensated liver disease, including cirrhosis, were eligible for inclusion. All patients had a liver biopsy within 3 years or a fibroscan within 6 months of randomization to determine fibrosis stage. For patients without a liver biopsy, fibrosis stage was determined by fibroscan results using a cut-off value of 9.5 kPa to indicate fibrosis stage ≥F3 (<9.5 kPa F0-F2; ≥9.5 kPa F3-F4), consistent with evaluations of the use of fibroscan in chronic HCV [18, 19] ; however, there are no reliable cut-offs in the literature for distinguishing <F3 from ≥F3. The fibroscan threshold for cirrhosis was ≥13 kPa, based on the results of a meta-analysis by Friedrich-Rust et al, and consistent with results of other studies [20, 21] . Main exclusion criteria included mixed-genotype HCV; HIV or hepatitis B co-infection; decompensated liver disease; and contraindications to peginterferon or ribavirin.
Asian patients were limited to 20% of the total population.
Study design
This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 study (Figure 1 Peginterferon (alfa-2a) was administered subcutaneously at 180 µg once weekly.
Ribavirin was administered orally at a total dose of 1000 or 1200 mg (for bodyweight <75 kg or ≥75 kg, respectively) daily in two divided doses, except in Japan where the total dose was 600, 800, or 1200 mg (for bodyweight ≤60 kg, >60-≤80 kg, or >80 kg, respectively) daily in two divided doses according to the local label. Both faldaprevir and ribavirin were given with food, a requirement of ribavirin but not faldaprevir administration. Dose reductions were permitted for peginterferon and ribavirin, and brief dose interruptions were permitted for all three drugs, but only if medically necessary and following discussion with the clinical monitor. Faldaprevir monotherapy was not permitted. Treatment compliance was monitored using pill counts and syringe counts at each visit.
Concomitant use of the following drugs was not permitted: immunomodulators (including chronic use of systemic corticosteroids); systemic antiviral agents (except for treatment of mild, localized, recurrent herpes simplex, or influenza); and medications that could cause phototoxicity (except ribavirin). Concomitant treatment with methadone or buprenorphine was excluded, and the use of substrates of Pglycoprotein, UGT1A1, CYP3A4, or CYP2C9 with a narrow therapeutic window was discouraged.
Study documentation, including protocol amendments, was approved by the appropriate institutional review board and the study was carried out in accordance with the Declaration of Helsinki and International Conference on Harmonisation guidelines. All patients provided written informed consent. An independent data monitoring committee reviewed the efficacy and safety data at regular intervals. All authors had access to the study data and reviewed and approved the final manuscript.
Randomization and blinding
Randomization was carried out using an interactive voice response system, and was stratified according to race (Black, Asian, other) and HCV genotype (genotype-1a, genotype-1b, other). Investigators, sponsor, and patients were blinded to treatment group allocation through the use of matching placebo capsules. HCV RNA results were blinded up to week 8.
Virologic endpoints
The primary endpoint was SVR (HCV RNA <25 IU/mL TND) 12 weeks after completion of therapy (SVR12). Secondary endpoints were ETS, and ALT and AST normalization. Other endpoints were rapid virologic response (RVR, HCV RNA <25 IU/mL TD or TND at week 4); complete EVR (cEVR, HCV RNA <25 IU/mL TND at week 12); and end of treatment response (ETR, HCV RNA <25 IU/mL TND at end of treatment).
HCV RNA levels were measured using the quantitative Roche COBAS ® Taqman HCV/HPS assay version 2 (lower limit of quantification 25 IU/mL; limit of detection 9-20 IU/mL).The primary endpoint was changed from SVR24 to SVR12 by a protocol amendment, consistent with evidence of concordance between SVR12 and SVR24 [22] .
Resistance monitoring
Samples were obtained for viral sequencing at baseline and at study visits. Baseline samples and samples from patients who did not achieve SVR12 were analyzed. Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS) [23] . Photosensitivity was graded as mild, moderate, or severe according to predefined criteria (see Supplementary tables). A rash management plan was used to reduce the progression of rash intensity and minimize the risk of photosensitivity. Patients were provided with sun protection and were instructed to protect eyes and skin from sun-or UV-light exposure using protection with a sun protection factor ≥30 providing UVA and UVB coverage.
Statistical analysis
Based on a sample size of 125 patients in the placebo arm and 250 patients in each of the faldaprevir arms, the study was anticipated to have a power of 96% to detect, with alpha = 0.05 (2-sided), an effect size of 20% for the primary endpoint, assuming an SVR12 of 50% in the placebo arm.
The primary efficacy analyses were based on the intention-to-treat (ITT) population (all randomized patients who received at least one dose of study medication). The safety analysis set included all patients who received at least one dose of study medication regardless of randomization.
The proportion of patients with SVR12 was compared pairwise using the CochranMantel-Haenszel test, stratified by race and genotype-1 subtype. A hierarchical testing strategy was pre-specified, with the test for the lower dose only interpreted if the higher dose was statistically significant. Thus, no alpha adjustment was necessary. ETS was summarized descriptively (numbers and proportions of patients reaching the endpoint in each arm). All other efficacy and safety data were summarized descriptively.
Positive and negative predictive values (PPVs and NPVs) for SVR12 based on different HCV RNA thresholds (1000 IU/mL, 100 IU/mL, 25 IU/mL, and detectable)
were calculated for all faldaprevir-treated patients with HCV RNA measurements at weeks 2, 4, 8, and 12 on treatment.
Results
Patients
Patients were enrolled from April 14 through November 11, 2011 at 102 sites from 10 European countries and Japan; the last patient completed follow-up on February 12, 2013. All patients were enrolled prior to the availability of telaprevir or boceprevir in Europe and Japan. Of 778 patients screened, 656 were randomized and 652 were treated with placebo (n=132), faldaprevir 120 mg (n=259), or faldaprevir 240 mg (n=261) (Figure 2 ). The baseline demographic characteristics were similar across the arms (Table 1) . Liver biopsies were available for 312/652 patients-115 (44%), 131
(51%), and 66 (50%) in the faldaprevir 120 mg, faldaprevir 240 mg, and placebo arms, respectively. Fibroscan scores were available for 353/652 patients-148
(57%), 138 (53%), and 67 (51%) in the faldaprevir 120 mg, faldaprevir 240 mg, and placebo arms, respectively. Efficacy SVR12 rates were significantly higher for faldaprevir 120 mg or 240 mg compared with placebo (79% and 80% compared with 52%, respectively; Table 2a ). The estimated differences in SVR12 of faldaprevir vs placebo were 27% (95% CI: [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] for faldaprevir 120 mg (P<.0001) and 29% (95% CI: 19-38) for faldaprevir 240 mg (P<.0001). The higher SVR12 rates with faldaprevir compared with placebo were also observed in subgroup analyses. SVR12 rates were similar for both doses of faldaprevir among all subgroups analyzed (Table 2b , Supplementary Figure 1) .
However, the number of patients in the cirrhotic subgroup was small.
Overall, 87% and 89% of patients in the faldaprevir 120 mg and 240 mg arms, respectively, achieved ETS (Table 2a) (faldaprevir 120 mg) and 88% (faldaprevir 240 mg) achieved SVR12.
Based on pooled data from both faldaprevir arms, week 4 HCV RNA <25 IU/mL resulted in a PPV (for SVR12) of 85%; week 4 HCV RNA undetectable resulted in a PPV of 90% (Supplementary Table 1 ). The NPV of week 4 HCV RNA ≥25 IU/mL was 87%, and of week 4 HCV RNA ≥100 IU/mL was 100%. Using a threshold of week 4
HCV RNA detectable (either TD or HCV-RNA quantifiable) resulted in an NPV of 50%, while using a threshold of week 12 HCV RNA detectable (i.e., not achieving cEVR) resulted in an NPV of 95%.
Breakthrough occurred in 42 patients across all treatment arms, 23 of whom were infected with HCV genotype-1a (Table 3) . Relapse occurred in 21%, 11%, and 9% of patients in the placebo, faldaprevir 120 mg, and faldaprevir 240 mg arms, respectively, and was more common in patients infected with genotype-1a (Table 3) .
One patient who received faldaprevir (0.2%) and 15 who received placebo (11%) had a null or partial response ( Table 4 .
Severe rash occurred in <1% of patients in each of the faldaprevir arms; no patient had life-threatening rash (Supplementary Table 5 ). Discontinuations of only faldaprevir or placebo due to rash occurred in two patients. Photosensitivity was infrequent (n=15, 2%), with the majority of events occurring in the faldaprevir 240 mg arm (10/15). All but two events were classified as mild (Supplementary Table 5 ) and no discontinuations were reported due to photosensitivity.
Grade 3-4 abnormalities in white blood cells, platelets, neutrophils, and lymphocytes occurred with similar frequency across the treatment arms (Supplementary Table 6 ).
There was no difference in hemoglobin levels between the treatment arms at any visit ( Figure 3 ). Up to week 24, proportions of patients with hemoglobin levels ≤10 g/dL and ≤8.5 g/dL were similar across treatment arms (Supplementary Table 6 ). Total bilirubin levels more than 2.6 times the upper limit of normal (ULN) were more frequent in the faldaprevir arms. More patients had elevated bilirubin in the faldaprevir 240 mg arm than the 120 mg arm (Supplementary Table 6 ). Bilirubin elevations were characterized by predominantly unconjugated bilirubin, peaked around week 4, and returned to baseline levels in all patients after the end of faldaprevir treatment (Supplementary Figure 2) . Four patients in the faldaprevir 240 mg arm had DAIDS Grade 3 or 4 total bilirubin and direct bilirubin:total bilirubin ratio >0.5. None of these patients had concurrent elevations in ALT or AST >3×ULN, or any clinical signs of liver injury.
Discussion
This study demonstrated that once-daily faldaprevir combined with peginterferon and ribavirin was significantly more effective than peginterferon and ribavirin alone in treatment-naïve patients with HCV genotype-1 infection. The majority of patients (88%) were eligible to receive 12 weeks of faldaprevir plus peginterferon and ribavirin and stop all treatment at week 24; of these patients, 88% achieved SVR12.
SVR12 rates were similar with the 120 mg and 240 mg doses of faldaprevir (79% and 80%, respectively), and significantly higher than with peginterferon and ribavirin alone (52%). An increase in SVR12 rates for faldaprevir over placebo was consistently observed across subgroups, although the study was not powered to assess statistical significance in the different subgroups and some subgroup comparisons are limited by small numbers. The increase in SVR12 for faldaprevir over placebo was higher in certain difficult-to-treat populations (HCV genotype-1a, high baseline HCV RNA, and IL28B non-CC) versus the easier-to-treat subgroup.
Common baseline polymorphisms were not found to affect the efficacy of faldaprevir.
The Q80K variant has been associated with reduced SVR12 in phase 3 studies of simeprevir [25, 26] ; however Q80K, present in 23% of genotype-1a-infected patients in this study, was not found to reduce SVR12 in faldaprevir-treated patients. As observed in phase 2 studies, RAVs encoding substitutions at positions R155
(genotype-1a) or D168 (genotype-1b) of HCV NS3 emerged in the majority of patients who did not achieve SVR12 [13, 14] .
While differences in patient populations and trial designs preclude direct comparison of these data with other studies, the 27% increase in SVR12 with faldaprevir plus peginterferon and ribavirin compared with peginterferon and ribavirin alone was similar to that reported in phase 3 trials of telaprevir (31% vs placebo), boceprevir (28% vs placebo), and simeprevir (30% vs placebo) plus peginterferon and ribavirin in treatment-naïve patients with HCV genotype-1 [2, 3, 25, 27] . More patients were able to stop treatment at week 24 with faldaprevir compared with telaprevir and boceprevir (88% vs 58% and 47%, respectively), although that may be due in part to different HCV RNA criteria used for shortening treatment duration in the different trials [2, 3] . Compared with simeprevir-treated patients, a similar proportion of faldaprevir-treated patients were able to stop at week 24 (88%) [25, 27] . In all trials, patients who qualified for shortened treatment achieved a high SVR (>83%) [2, 3, 25, 27] .
Analysis of the predictive value of certain virologic endpoints suggests that a week 4 stopping rule for faldaprevir plus peginterferon and ribavirin should not use a threshold of detectable HCV RNA: 50% of patients who met this criterion went on to achieve SVR12 with continued treatment. A week 4 stopping rule using a threshold of ≥25 IU/mL (NPV 87%) or ≥100 IU/mL (NPV 100%) would more reliably stop treatment in patients unlikely to achieve cure.
The higher (240 mg QD) dose of faldaprevir was associated with a minor increase in AEs compared with the lower (120 mg QD) dose or compared with peginterferon and ribavirin alone. The rate of treatment discontinuation was similar between the faldaprevir 120 mg and placebo arms, and only slightly higher in the faldaprevir 240 mg arm. The addition of faldaprevir increased the rate of rash observed with peginterferon and ribavirin alone. However, the incidence of rash was similar with both faldaprevir doses and was mainly mild in intensity. Photosensitivity reactions were rare, supporting the use of sun protection during treatment with faldaprevir.
Grade 2-4 GI events were more common in the faldaprevir 240 mg arm, and treatment discontinuation due to GI toxicities only occurred with this higher dose.
These data indicate that faldaprevir may have a more favorable tolerability profile compared with telaprevir and boceprevir. While real-world data indicate that severe anemia is one of the most common AEs reported with first-wave PIs [28, 29] , faldaprevir did not increase the proportion of patients with hemoglobin levels below 10 g/dL or 8.5 g/dL compared with placebo.
As observed in phase 2 studies, faldaprevir was associated with a dose-dependent, transient, and benign elevation in predominantly unconjugated bilirubin [13, 14] .
Bilirubin levels returned to baseline after faldaprevir was stopped (Supplementary Figure 2) . Faldaprevir inhibits the bilirubin conjugation enzyme, UGT1A1, and to a lesser extent the bilirubin transporters, OATP1B1, and MRP2 [30] . Increases in bilirubin have also been observed with simeprevir; however, this is predominantly driven by inhibition of OATP1B1 and MRP2 [31] .
A possible limitation to this study is that investigators were unblinded to HCV RNA results after week 8, which could have effectively unblinded the treatment allocation.
In addition, the effects of faldaprevir on bilirubin could have been used to infer treatment allocation. However, few patients withdrew consent in this study, so the effect is likely to be negligible. Another potential limitation is the lack of baseline histology data on many patients due to the widespread use of fibroscan in Europe.
For patients without liver biopsies, we relied on fibroscan scores to stage fibrosis;
although the fibroscan cut-off for cirrhosis is quite established, there is some disagreement about the optimal cut-off value for distinguishing <F3 from ≥F3 fibrosis [18] [19] [20] [21] . Nevertheless, there is no gold standard for defining fibrosis stage at all, since sampling error is a major problem with inadequate sized liver biopsies [32] .
In addition to the results presented here, faldaprevir has shown efficacy as part of an interferon-based regimen for treatment-experienced patients (STARTVerso3) [33] , and as part of an interferon-free regimen [34] . Regional differences in the cost of HCV therapies may lead to continued use of interferon-based regimens for the foreseeable future. Regimens that have been approved for treating genotype-1 infection include sofosbuvir plus pegylated interferon and ribavirin [35] and simeprevir plus pegylated interferon and ribavirin [25, 27] . For patients ineligible for interferon, sofosbuvir plus simeprevir with or without ribavirin is recommended [36] .
In conclusion, this phase 3 trial demonstrated that faldaprevir plus peginterferon and ribavirin significantly increased SVR12 in HCV genotype-1-infected treatment-naïve patients compared with peginterferon and ribavirin alone. While efficacy was similar for both doses of faldaprevir across all subgroups examined, the lower dose (120 mg) was better tolerated, specifically regarding GI events and photosensitivity. Since the completion of this study, faldaprevir development has been terminated for nonmedical reasons in view of the fast progress in development of interferon-free regimens, and several all-oral direct-acting antiviral regimens have demonstrated high SVR12 rates with 12 weeks of treatment [37, 38] . The results of the current study mark an important milestone in HCV therapeutics, demonstrating the commitment of patients and investigators to HCV research and attesting to the rapid pace at which the field has evolved. Tables   Table 1. Baseline demographics and (20) 2 (2) 52 (20) 3 (1) 51 (20) 4 (2) Other † 0 1 (<1) 1 (<1) (17) 2 (1) 42 (16) 0 Cirrhosis ǁ , n (%) 8 (6) 16 (6) 15 ( without a liver biopsy (<F3 = <9.5 kPa, ≥F3 = ≥9.5 kPa) [18, 19] . If a patient was indicated to have cirrhosis but had neither biopsy nor fibroscan data, they were classified as having ≥F3 fibrosis. *Confirmed increase in HCV RNA ≥1 log 10 from nadir or ≥25 IU/mL after an initial decrease to <25 IU/mL. † Null response, absence of HCV RNA drop by ≥2 log 10 from baseline at week 12; partial response, ≥2 log 10 decrease in HCV RNA from baseline at week 12, but not achieving HCV RNA <25 IU/mL TND by end of treatment. ‡ HCV RNA >25 IU/mL during follow-up (up to SVR12 visit) after decrease to <25 IU/mL TND at end of treatment.
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